[
  {
    "ts": null,
    "headline": "Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121",
    "summary": "REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS IÂ &Â II. Learn more on RGNX stock here.",
    "url": "https://finnhub.io/api/news?id=ab2df99813f6cc56cf0bd31f5bb520ff65ae23366f744fc671fc4e371aa3989b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737046766,
      "headline": "Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121",
      "id": 132411104,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148124381/image_2148124381.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS IÂ &Â II. Learn more on RGNX stock here.",
      "url": "https://finnhub.io/api/news?id=ab2df99813f6cc56cf0bd31f5bb520ff65ae23366f744fc671fc4e371aa3989b"
    }
  },
  {
    "ts": null,
    "headline": "Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026",
    "summary": "Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Read why I'm bullish on RGNX stock.",
    "url": "https://finnhub.io/api/news?id=a51921c75dfbed3781075b2e3e8769e0cf3c4eaa5984368796bde7c80709edde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737000070,
      "headline": "Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026",
      "id": 132404286,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174684814/image_2174684814.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Read why I'm bullish on RGNX stock.",
      "url": "https://finnhub.io/api/news?id=a51921c75dfbed3781075b2e3e8769e0cf3c4eaa5984368796bde7c80709edde"
    }
  }
]